Patients with type 2 diabetes receiving once-weekly insulin icodec were more likely to reach a hemoglobin A1C level below 7% compared to those who received once-daily insulin analogues.
Data from a pair of phase 3a trials presented at ADA 2023 provide clinicians with new insight into the effects of once-weekly insulin icodec relative to daily insulin degludec.
New data show once-weekly insulin icodec met additional endpoints in adults with type 2 diabetes in phase 3a trials streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.